Lymphatic filariasis (LF) is an avoidable, debilitating, disfiguring disease caused by infection with the filarial parasites Wuchereria bancrofti, Brugia malayi and B. timori. Globally, 51.4 million people are
estimated to be infected. Lymphoedema and hydrocoele are the visible, chronic clinical co...nsequences of the lymphatic vessel impairment caused by infection with these parasites. Mosquitos in the genera Culex, Anopheles, Mansonia and Aedes transmit the parasites from person to person. 2020 marked the 20th year since WHO established the Global Programme to Eliminate Lymphatic Filariasis (GPELF) which aims to stop transmission of infection with mass drug administration (MDA) and to alleviate suffering among people affected by the disease through morbidity management and disability prevention (MMDP).
more
Leishmaniasis is a major vector-borne disease caused by obligate intramacrophage protozoa of the genus Leishmania, and transmitted by the bite of phlebotomine female sand flies of the genera Phlebotomus and Lutzomyia, in the old and new worlds, respectively. Among 20 well-recognized Leishmania speci...es known to infect humans, 18 have zoonotic nature, which include agents of visceral, cutaneous, and mucocutaneous forms of the disease, in both the old and new worlds. Currently, leishmaniasis show a wider geographic distribution and increased global incidence. Environmental, demographic and human behaviors contribute to the changing landscape for zoonotic cutaneous and visceral leishmaniasis. The primary reservoir hosts of Leishmania are sylvatic mammals such as forest rodents, hyraxes and wild canids, and dogs are the most important species among domesticated animals in the epidemiology of this disease. These parasites have two basic life cycle stages: one extracellular stage within the invertebrate host (phlebotomine sand fly), and one intracellular stage within a vertebrate host. Co-infection with HIV intensifies the burden of visceral and cutaneous leishmaniasis by causing severe forms and more difficult to manage. The disease is endemic to Ethiopia, and the clinical signs are not pathognomic. The visceral form (Kala-azar) may be confused with other similar conditions such as malaria, tropical splenomegaly, schistosomiasis, milliary tuberculosis, and brucellosis. Similarly, cutaneous leishmaniasis should be differentiated from disease like tropical ulcers, impetigo and leprosy. There are several methods of laboratory diagnosis of leishmaniasis, including parasitological, immunological and molecular. Different forms of treatments are available including oral, parenteral, and topical medications such as pentavalent antimonials, liposomal amphotericin B, miltefosine and paromomycin. Methods of control are largely limited to destruction of animal reservoirs, treatment of infected humans, and management of sand fly populations. Development of an effective vaccine against leishmaniasis has been largely unsuccessful and hinders its prevention.
more
Leishmaniasis is found in people in focal areas of approximately 90 countries in the tropics, subtropics, and southern Europe. The ecologic settings range from rain forests to deserts. Leishmaniasis usually is more common in rural than in urban areas, but it is found in the outskirts of some cities.... Climate and other environmental changes have the potential to expand the geographic range of the sand fly vectors and the areas in the world where leishmaniasis is found.
more
Education and information about Chagas Disease epidemiology and risk factors.
Microbes like bacteria, fungus and viruses are becoming resistant to medicines like antibiotics. WHO has declared antimicrobial resistance as a global health and developmental threat. How can we stop antimicrobial resistance? Dr Hanan Balkhy explains in Science in 5
Canadian Journal of Microbiology 25 June 2021 https://doi.org/10.1139/cjm-2020-0572
2023 will mark the 75th year of the World Health Organization. The world has achieved many public health milestones in these 75 years. In Science in 5 today we will take a look into the future - to understand what are the innovations we can expect and what will be some of our biggest challenges. Her...e to paint us a picture of what Health for All would look like in the future is WHO's Chief Scientist, Dr Soumya Swaminathan.
more
Guide pratique à l’usage des médecins, infirmiers, techniciens de laboratoire, auxiliaires de santé, techniciens sanitaires et logisticiens
Practical guide for doctors, nurses,laboratory technicians, medical auxiliaries,water and sanitation specialists and logisticians
Practical guide for doctors, nurses,laboratory technicians, medical auxiliaries,water and sanitation specialists and logisticians. Online version
Por el Sendero de Epilepsia Ges 2016 Niños y Adultos
Clasificación de las Crisis
mRNA technologies. What is their future and scope, and what are the challenges that countries might face in rolling them out? Hello and welcome to Science in5. I'm Vismita Gupta-Smith. We are talking to Dr.Soumya Swaminathan today. Soumya, talk to us about mRNA technologies. What is the future?
WHO’s Dr Philippa Easterbrook gives a situation update on the recent hepatitis outbreak affecting children including possible causes and steps parents, caregivers and countries should take.
Which communities are most at risk of Monkeypox in the current outbreak and why? WHO’s Andy Seale explains how we can support the communities at risk in Science in 5.
What are the symptoms of monkeypox? Who is at risk and how can we protect ourselves? Why is WHO concerned about it? WHO’s Dr Rosamund Lewis explains in Science in 5.
29 April 2022
What are the new vaccines in the pipeline? What are the challenges to turning vaccines into vaccination ? What timelines can we expect for future vaccines? WHO’s Dr Katherine O’Brien explains in Science in 5.
4 march 2022
What have we learned about the symptoms of Long COVID or Post COVID-19 condition so far? How long does it last, when should you worry, and what treatments are recommended? WHO’s Dr Janet Diaz explains in Science in 5.
Janvier 2022.
L'une des nombreuses inégalités entre les sexes dans le secteur de la santé et des soins que COVID-19 a révélées concerne l'ajustement et la conception des équipements de protection individuelle (EPI). L'apparition rapide et l'ampleur de COVID-19 ont entraîné des pénuries d'...EPI dans la plupart des pays, provoquant des infections et des décès évitables parmi les travailleurs de la santé et d'autres personnes en première ligne. Bien que la plupart des travailleurs de la santé soient des femmes, les spécifications de fabrication des EPI médicaux sont généralement établies en fonction du corps masculin et de nombreux cas d'EPI non conçus pour le corps des femmes ont été signalés. WGH a entrepris un projet de recherche mondial afin de documenter les défis auxquels les travailleuses de la santé sont confrontées.
more
Are you aware of the medical waste generated during the pandemic? How does it impact your health and what can you do to reduce it? WHO’s Dr Margaret Montgomery explains in Science in 5.